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Abstract
Background
Elevated plasma concentrations of the endogenous nitric oxide synthase (NOS) inhibitor
asymmetric dimethylarginine (ADMA) have been observed in respiratory conditions such as
asthma and cystic fibrosis. Since oxidative stress has been shown to increase the activity of
arginine methylating enzymes, hence increased ADMA synthesis, and to reduce ADMA
degrading enzymes, hence increased ADMA concentrations, we assessed methylated argi-
nines concentrations in chronic obstructive pulmonary disease (COPD), a disease charac-
terized by increased oxidative stress.
Methods
Plasma arginine, ADMA and symmetric dimethylarginine (SDMA), oxidative stress mark-
ers (thiobarbituric acid reactive substances, TBARS, and plasma proteins SH, PSH) and
antioxidants (taurine and paraoxonase 1, PON1, activity) were measured in 43 COPD
patients with mild (n = 29) or moderate (n = 14) disease and 43 age- and sex-matched
controls.
Results
TBARS significantly increased with COPD presence and severity (median 2.93 vs 3.18 vs
3.64 μmol/L, respectively in controls, mild and moderate group, p<0.0001 by ANOVA)
whereas PSH decreased (6.69±1.15 vs 6.04±0.85 vs 5.33±0.96 μmol/gr prot, p<0.0001 by
ANOVA). Increased ADMA/arginine ratio, primarily due to reduced arginine concentrations,
was also observed with COPD presence and severity (median 0.0067 vs 0.0075 vs 0.0100,
p<0.0001 by ANOVA). In multiple logistic regression analysis, only TBARS (OR 0.44, 95%
CI 0.25–0.77; p = 0.0045) and ADMA/Arginine ratio (OR 1.72, 95% CI 2.27–13.05; p = 0.02)
were independently associated with COPD severity.
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Conclusion
COPD presence and severity are associated with increased oxidative stress and alterations
in arginine metabolism. The reduced arginine concentrations in COPDmay offer a new tar-
get for therapeutic interventions increasing arginine availability.
Introduction
Chronic Obstructive Pulmonary Disease is a common respiratory condition characterized by
progressive airflow limitation, persistent productive cough, mucous plugging and dyspnea [1–
2]. Elevated concentrations of oxidative stress (OS) markers are commonly observed in this
group [3–5]. The reduced ability of cellular antioxidant defenses to fully inactivate the reactive
oxygen species (ROS) is a hallmark of OS. As a result, there is a functional impairment of sev-
eral important biomolecules as lipids, proteins or nucleic acids, which can compromise cell
health and viability. OS induces a variety of cellular responses through generation of secondary
reactive species, leading to cell death by necrosis or apoptosis and, consequently, disease onset
and progression. Moreover, activity of several enzymes can be influenced by redox regulation
[6], including enzymes involved in the formation and degradation of asymmetric dimethylargi-
nine (ADMA), such as protein arginine N-methyltransferases (PRMTs) and dimethylarginine
dimethylaminohydrolase (DDAH) [7–8]. ADMA is an effective endogenous inhibitor of nitric
oxide synthase (NOS). Its accumulation has been reported in renal failure [9–10], cardiovascu-
lar disease [11–12] and, only recently, lung disease [13–14]. ADMA synthesis is catalysed by
PRMTs through the addition of one or two methyl groups to the terminal nitrogen atom of
protein arginine. Human PRMTs are classified on the basis of their specific catalytic activities
in type I and type II. In the first step, both enzymes catalyse monomethylarginine formation.
During the second step type I enzymes produce ADMA, whereas type II enzymes lead to the
formation of SDMA [15]. During proteolysis, ADMA and SDMA are released into the cytosol
where free ADMA, but not free SDMA, is further degraded to citrulline and dimethylamine by
DDAH15. Studies have shown that PRMT1 RNA or protein expression is increased, and
DDAH activity is decreased, under OS stimuli [16–18]. While OS is well characterized, little
information is available on methylated arginine concentrations in COPD. Available data prin-
cipally focus on arginine and methylated arginines in sputum or exhaled breath condensate
[19–22], while only one report describes plasma concentrations in COPD subjects [22]. There-
fore, we tested the hypothesis that a) methylated arginines are associated with COPD presence
and severity and b) such alterations are associated with OS markers (thiobarbituric acid reac-
tive substances and Proteins–SH) and antioxidants (taurine and paraoxonase 1 activity).
Methods
Subjects
Forty-three consecutive COPD patients (29 mild and 14 moderate) without a previous diagno-
sis of COPD, were enrolled from the Respiratory Unit of the University of Sassari. Each patient
underwent physical examination, chest radiographs, routine blood tests and respiratory func-
tion tests. The latter included forced expiratory volume in 1 sec (FEV1), forced vital capacity,
and FEV1/FVC ratio. A structured questionnaire was administered to obtain demographic and
clinical information including age, sex, body mass index (BMI) and smoking status. No patient
was treated with long-acting muscarinic antagonists, long or short acting β-agonists at the time
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of the assessments. Moreover, no patient received inhaled corticosteroids within four weeks
prior to the study. COPD patients with significant symptom deterioration within the last three
months, indicative of disease exacerbation, were excluded.
COPD diagnosis and severity were assessed according to physical examination, spirometric
results,
smoking history and respiratory symptoms based on the Global Initiative for Chronic
Obstructive Lung Disease criteria [23]. In particular, classification of COPD severity was based
on spirometric values reported in Table 1.
A group of 43 age and sex-matched healthy controls was also included in the study. Exclu-
sion criteria included the presence of concomitant inflammatory disease such as autoimmune
disorders and infections, liver, kidney, heart disease and cancer.
This study was approved by the Institutional Local Ethics Committee (Azienda Sanitaria
Locale n°1 di Sassari (Italy) (prot. 2175/CE del 21/04/2015), and was in accordance with the
principles of Declaration of Helsinki. All subjects provided written informed consent.
Biochemical analysis
Arginine, ADMA, SDMA and taurine were determined by capillary electrophoresis UV detec-
tion as previously described [24–25]. As inadequate precision of the assay used for the analysis
of ADMAmay increase the chance of statistical type 2 errors in clinical studies and may also
lead to a severe underestimation of the strength of the association between ADMA and other
biochemical or clinical variables [26], we used a capillary electrophoresis method that give
inter-assay CV between 2 and 3% for Arginine, ADMA and SDMAmeasurement.
TBARS were determined according to the method described by Esterbauer and Cheeseman
[27]. TBARS methodology measures MDA and other aldehydes produced by lipid peroxida-
tion induced by hydroxyl free radicals. Plasma was mixed with 10% trichloroacetic acid and
0.67% thiobarbituric acid and heated at 95°C in a thermoblock heater for 25 min. TBARS were
determined by measuring the absorbance at 535 nm. A calibration curve was obtained using
standard MDA and each curve point was subjected to the same treatment as that of the sam-
ples. Paraoxonase activity was determined by measuring the increase in absorbance at 412 nm
(formation of 4-nitrophenol) using paraoxon (O,O diethyl-O-p-nitrophenyl phosphate) as a
substrate [28]. Enzyme activity was calculated by using the molar extinction coefficient of
17,100 M−1cm−1 and one unit (U) of paraoxonase activity was defined as 1 nmoL of 4-nitro-
phenol formed per minute. Plasma PSH determination was performed by spectrophotometry
with 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) as titrating agent by measuring the absorbance
of conjugate at 405 nm [29]. Concentration in samples was determined from a GSH standard
curve.
Statistical analysis
All results are expressed as mean values (mean ± SD) or median values (median and range).
Variables distribution was assessed by the Kolmogorov-Simirnov test. Statistical differences
Table 1. Classification of COPD severity on the basis of spirometry values.
Severity of obstruction Post bronchodilator FEV1/FVC FEV1% PRED
MILD COPD < 0.7 > 80%
MODERATE COPD < 0.7 50–80%
SEVERE COPD < 0.7 30–50%
VERY SEVERE < 0.7 < 30%
doi:10.1371/journal.pone.0160237.t001
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between groups were compared using unpaired Student’s t-test or Mann-Whitney rank sum
test, as appropriate. Correlation analysis between variables was performed by Pearson's correla-
tion or Spearman’s correlation as appropriate. Multiple comparisons were performed by one-
way ANOVA. Levene's test for equality of error variances was employed, while student-New-
man-Keuls test for all pairwise comparisons was used. Non-normally distributed variables
were log10-transformed prior to being used with parametric tests. Normal distribution of the
residuals was checked to assess the goodness of fit of the transformations.
Logistic regression analysis with COPD absence vs. presence as dependent variable was con-
ducted to determine associations between variables potentially involved in disease develop-
ment. A further logistic regression analysis with mild or moderate condition as dependent
variable was conducted to determine associations between COPD severity and variables poten-
tially involved in disease progression.
Statistical analyses were performed using MedCalc for Windows, version 15.4 64 bit (Med-
Calc Software, Ostend, Belgium) and SPSS for Windows, version 14.0 32 bit (IBM Corporation;
Armonk, NY, USA).
Results
Table 2 describes the clinical and demographic characteristics of COPD patients and age- and
sex-matched controls. FEV1 decreased significantly from 2.75±0.59 L in controls to 2.24±0.56
L in mild and 1.56±0.32 L in moderate COPD patients (p<0.001), whereas FVC was 3.40±0.73
L, 3.18±0.77 L and 2.44±0.54 L, respectively (p<0.001). FEV1/FVC ratio was 80.4±4.9% in con-
trols, 70.2±3.12% in mild, and 64.8±7.9% in moderate COPD patients, respectively (p<0.001).
Table 2. Clinical, functional and biochemical parameters of healthy subjects and COPD patients.
Characteristics Controls (n = 43) Mild COPD (n = 29) Moderate COPD (n = 14) p value
Age (years) 73.4±6.9 75.4±4.8 73.4±7.7 NS
Sex (F/M) 9/34 7/22 2/12 NS
BMI (kg/m2) 26.4±3.6 27.4±3.4 27.4±4.5 NS
Current smokers 3 (7%) 2 (6.9%) 1 (7.1%) NS
Never smoked 14 (32.6%) 8 (27.6%) 2 (14.2%) NS
Ex smokers 26 (60.4%) 19 (65.5%) 11 (78.6%) NS
FEV1 (L) 2.75±0.59 2.24±0.56*** 1.56 ± 0.32***°°° <0.001
FVC (L) 3.40±0.73 3.18±0.77 2.44±0.54***°° <0.001
FEV1/FVC 80.8±4.9 70.2±3.1*** 64.8±7.9***°° <0.001
TBARS (μmol/L) 2.93 (2.46–3.23) 3.18 (2.50–3.54) 3.64 (3.16–4.38)**° 0.003
PSH (μmol/ g prot) 6.69±1.15 6.04±0.85 5.33±0.96***° <0.001
PON1(U/L) 253 (147–340) 230 (154–376) 211(157–284) NS
Taurine (μmol/L) 55.8 (47.7–72.1) 59.3 (49.0–76.8) 57.6 (50.8–75.3) NS
Arginine (μmol/L) 79.8 (68.3–90.4) 70.4 (60.3–78.2)* 53.4 (41.4–59.8)***°° <0.001
ADMA (μmol/L) 0.488 (0.454–0.544) 0.505 (0.432–0.588) 0.513 (0.412–0.625) NS
SDMA (μmol/L) 0.460 (0.395–0.590) 0.513 (0.429–0.594) 0.485 (0.456–0.577) NS
ADMA/arginine 0.0067 (0.0056–0.0077) 0.0075 (0.0053–0.0098) 0.0100 (0.0079–0.0117)***°° <0.001
ADMA/SDMA 1.07 (0.80–1.28) 0.98 (0.81–1.31) 1.12 (0.86–1.25) NS
*P<0.05
**p<0.01
***p<0.001 vs Controls;
°P<0.05
°°p<0.01
°°°p<0.001 vs mild COPD obtained by ANOVA (Student-Newman-Keuls test for all pairwise comparisons or Krustall-Wallis test as appropriate)
doi:10.1371/journal.pone.0160237.t002
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TBARS plasma concentrations increased significantly with COPD presence and severity
(p<0.001 by ANOVA). In particular we found a significant difference between controls and
patients with moderate COPD (median 2.93 vs 3.64 μmol/L, p<0.01) and between mild and
moderate COPD patients (median 3.18 vs 3.64 μmol/L, p<0.05). By contrast, a significant
decrease in plasma PSH concentrations was observed with COPD presence and severity
(p<0.001). Multiple comparisons by ANOVA showed significant differences in PSH mean val-
ues between controls and moderate COPD (6.69±1.15 μmol/g prot vs 5.33±0.96 μmol/g prot,
p<0.001) and between mild and moderate COPD (6.04±0.85 vs 5.33±0.96 μmol/g prot
P<0.001). ADMA and SDMA plasma concentrations were not significant different between
controls and COPD patients. By contrast, median arginine concentrations were progressively
lower in controls (79.8 μmoL), mild (70.4 μmol/L) and moderate COPD patients (53.4 μmolL,
P<0.001). As consequence also ADMA/arginine showed significant differences according to
COPD presence and severity (p = 0.0001). Multiple comparisons demonstrated a significant
difference between controls and patients with moderate COPD (median 0.0067 vs 0.0100,
p<0.001) and between mild and moderate group (median 0.0075 vs 0.0010, p<0.05).
As reported in Table 3, univariate analysis in COPD patients showed that FEV1 was corre-
lated with age (rho = -0.31, p = 0.043), PSH (rho = 0. 36, p = 0.016) and ADMA/arginine ratio
(rho = -0.43, p = 0.0001). In controls FEV1 was correlated only with age (rho = -0.34;
p = 0.036) and sex (rho = -0.55, p<0.0001). Table 4 report as, after adjusting for age, sex, BMI,
smoking status, TBARS, PSH and ADMA/arginine ratio, sex (β = -0.44, p = 0.007), PSH (β =
0.33, p = 0.047), and ADMA/arginine ratio (β = -0.45, p = 0.005) were independently associ-
ated with FEV1 in COPD patients in regression analysis. In controls, only age (β = -0.38,
p = 0.009) and sex (β = -0.68, p =<0.0001) were independently associated with FEV1.
When considering controls and COPD patients together, a negative relationship between
PSH and ADMA/arginine ratio was also observed (rho = -0.23, p = 0.033). In multiple logistic
regression analysis of the total population (COPD and controls), after adjusting for age, sex,
BMI, smoking status, ADMA/arginine ratio, TBARS, PSH, PON and taurine, only PSH (OR
0.44, 95% CI 0.25–0.77; p = 0.004) and ADMA/Arginine ratio (OR 172, 95% CI 2.27–13,055;
p = 0.02) were independently associated with presence of COPD.
Table 3. Linear regression analysis between FEV1 and some demographic and biochemical variables
in controls and COPD patients.
Controls (n = 43) COPD (n = 43)
r or rho p-value r or rho p-value
Age -0.34 0.036 -0.31 0.043
Sex -0.55 <0.0001 – –
PSH – – 0.36 0.016
ADMA/Arginine – – -0.43 <0.0001
doi:10.1371/journal.pone.0160237.t003
Table 4. Multiple regression analysis with FEV1 as dependent variable and age, sex, BMI, smoking
status, TBARS, PSH and ADMA/arginine ratio as independent variables, in controls and COPD
patients.
Controls (n = 43) COPD (n = 43)
β p-value β p-value
Age -0.38 0.009 – –
Sex -0.68 <0.0001 -0.44 0.007
PSH – – 0.33 0.047
ADMA/Arginine – – -0.45 0.005
doi:10.1371/journal.pone.0160237.t004
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Data of multiple logistic regression analysis performed on 43 COPD patients according to
disease severity (mild vs. moderate), after adjusting for age, sex, BMI, smoking status, ADMA/
arginine ratio, TBARS, PSH, PON and taurine are reported in Table 5. Lower plasma PSH and
higher TBARS and ADMA/arginine ratio were independently associated with disease severity.
Discussion
Chronic obstructive pulmonary disease is a major and increasing global health problem.
According to the World Health Organization COPD will become the third leading cause of
death and the fifth leading cause of disability in the world by 2020 [30]. Despite increasing
awareness, the pathogenesis of COPD has received relatively little attention from clinicians,
researchers, and the pharmaceutical industry [31]. This is likely due because COPD is viewed
as self-inflicted (by smoking) and also because the underlying disease process is generally con-
sidered to be irreversible. Consequently, there is a fundamental lack of knowledge about the
cellular, molecular, and genetic mechanisms of this pathology. COPD is associated with a
chronic inflammatory response, predominantly in small airways and lung parenchyma, which
is characterized by an increase of activated neutrophils and macrophages and increased num-
bers of inflammatory mediators in the airways [32–33]. It has been proposed that in COPD the
increased oxidant burden may not be adequately counterbalanced by the lung antioxidant sys-
tems, resulting in OS. Increased OS may be induced both directly, as a result of smoking, or
indirectly by the increased release of reactive oxygen species from airspace inflammatory cells
stimulated by noxious particles and gases. Analysis of cell profile in alveoli and small airways
of COPD patients shows, in fact, an increase in several inflammatory cell types, including mac-
rophages, T lymphocytes, B lymphocytes, and neutrophils [34]. These cells, once activated, can
generate anion superoxide (O2-) probably through reduced nicotinamide adenine dinucleo-
tide phosphate oxidase pathway. In addition, the impaired ventilation may results in a
decreased hemoglobin oxygen saturation level (hypoxemia), resulting in local tissue hypoxia
[35]. Experimental evidence suggests that hypoxaemia enhances OS in COPD [36] and that the
source of ROS production in hypoxia is likely to be the mitochondria at the respiratory chain
level [37]. In support of these observations we found increased concentrations of TBARS (+-
13.2%) and reduced concentrations of PSH (-13.3%) in COPD subjects vs. controls, indicating
the presence of significant OS. PSH assay, in fact, provide a measure of total protein sulfhydryl
groups in plasma. The most representative -SH group in plasma is that of human serum albu-
min, due to its high concentrations. The Cys34 –SH group of HSA represents ~80% of all
reduced thiols in human plasma. It is an important scavenger of reactive oxygen and nitrogen
species in blood acting as an effective redox buffer in the vascular compartment [38]. When
oxidative stress compromise this redox buffer system, ROS are free to attack lipids, thus yield-
ing some products of lipid peroxidation as malondialdehyde, measurable by TBARS assay.
Interestingly, simple linear regression suggests that in COPD patients, FEV1 is associated with
age, PSH and ADMA/Arginine ratio, while in controls only age and sex were related to FEV1.
Table 5. Logistic regression analysis (including TBARS, PSH and ADMA/arginine ratio) showing ORs
for moderate disease.
Factor Moderate disease p-value
OR 95%CI
TBARS 481 x1012 26–9x1027 0.030
PSH 0.0125 0.0003–0.4731 0.018
ADMA/arginine 49x106 25–96x1012 0.016
doi:10.1371/journal.pone.0160237.t005
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These data, further supported by multiple linear regression analysis after correction for other
important variables, confirms that increased OS is strictly linked to deterioration in lung func-
tion. Moreover, similarly to our previous observations in the general older population [39], we
found a significant negative association between ADMA/arginine ratio and FEV1, suggesting a
detrimental effect of arginine methylation on key lung functional parameters. This observation
was further confirmed by multiple logistic regression analysis indicating that PSH and ADMA/
arginine ratio were independently associated with COPD development. When analyzing the
factors independently associated with COPD severity both OS markers, PSH and TBARS, and
ADMA/arginine ratio showed significant associations. Arginine metabolism plays an impor-
tant role in the maintenance of airways tone and function by production of nitric oxide via the
NOS pathway [40]. Dysregulation of the competing enzymes has been shown to contribute to
airway obstruction in asthma and in patients with cystic fibrosis [13–14,21]. Bode-Boger and
coworkers recently proposed the calculation of the ADMA/arginine ratio as an index reflective
of NOS imbalances activity caused by the accumulation of ADMA. As such, a “normal”
ADMA/arginine ratio is in the range of 0.0044–0.0076 [40], consistent with our reported values
in the control group, while COPD subjects had higher values in accordance with recent data
reported by Aydin et al. [22]. In this last report, however, there is no information regarding the
impact of disease severity on ADMA concentrations. We found that, when categorizing on the
basis of disease progression, only moderate COPD patients had values above the normal range,
whereas mild COPD patients had median values in the normal range, further supporting the
hypothesis that ADMA and arginine could be involved primarily during disease worsening.
Pending additional evidence from experimental and human studies, it is plausible to speculate
that COPD disease exacerbation states are associated with further increases both in oxidative
stress and in the ADMA/Arginine ratio. The mechanisms responsible for the reported imbal-
ance between ADMA and arginine may be related to OS. The reduction in arginine concentra-
tions observed in COPD patients is likely due to the well-known increase of arginase activity
stimulated by OS [41]. Moreover, the increase of neutrophil numbers typical of COPD may
contribute to arginine depletion since these cells constitutively express high levels of arginase I
in azurophilic granules. These granules may be released in patients with COPD together with
other constituents of the granules such as elastase [42]. It is also known that neutrophil num-
bers increase as COPD worsens [43]. This might further explain the further reduction of argi-
nine concentrations observed in moderate vs. mild forms of disease.
Moreover, the activity of the enzymes involved in the formation and degradation of ADMA
such as PRMTs and DDAH is regulated in a redox-sensitive fashion [16–18]. Studies in cul-
tured endothelial cells have reported that the gene expression of PRMTs is increased by oxLDL
in a concentration-dependent manner [7]. There is growing body of evidence that OS decreases
the activity of the ADMA demethylating enzyme, DDAH [8]. The presence of a reactive cyste-
ine residue (Cys249) in the active site of DDAH leads to diminished activity of the enzyme in
presence of ROS. Thus, OS, through DDAH inhibition, PRMTs synthesis stimulation and argi-
nase increase activity might be primarily responsible for an imbalance of ADMA/arginine
ratio. This hypothesis is also supported by the significant negative correlation observed
between ADMA/arginine ratio and PSH in the analyzed subjects. In our COPD cohort,
ADMA/arginine ratio is altered mainly because of a reduction in arginine concentrations, even
if a non significant increase in ADMA levels of about 3.5% has been found in all COPD
patients with a rise of about 5.2% in moderate COPD. It will be interesting to evaluate if
ADMA concentrations are further increased in patients with more severe symptoms (COPD
stages 3 and 4).SDMA concentrations and ADMA/SDMA ratios were also similar in controls
and COPD patients. Obtained ADMA/SDMA values were besides in accordance to that
reported by Bulau et al [42].
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Therefore, our data indicate that OS and ADMA/arginine ratios are related in COPD
patients, confirming previous reports showing reduced PRMT RNA or protein expression,
arginase and DDAH activity under OS stimuli [16–18, 43–44]. Both PRMT and DDAH are
widely expressed in lung tissue. Recent evidence also suggest that methylarginine metabolism
in the lung may significantly contribute to circulating ADMA and SDMA concentrations [42].
In particular, pulmonary DDAH-1 is actively involved in ADMA degradation while PRMT-I
pulmonary expression is related to increased protein arginine methylation of the lung prote-
ome. Moreover, as previously discussed, neutrophils significantly contribute to arginine
decrease in the lung through the release of arginase I. Although no specific assessment of the
expression and activity of these enzymes in lung tissue was performed in our study, it is plausi-
ble that the structural and functional lung alterations in COPD may lead to changes in arginine
metabolites plasma concentration.
In conclusion our data, while confirming the role of OS and imbalanced arginine concentra-
tions in COPD patients, show for the first time that increased ADMA/arginine ratio is inde-
pendently associated with OS and COPD severity. Further studies, with a larger number of
subjects covering all stages of COPD disease, are required to fully characterize the impact of
arginine and ADMA on disease worsening.
Acknowledgments
A Visiting Professorship granted to Professor Mangoni by the Department of Biomedical Sci-
ences, University of Sassari (Italy), facilitated this work.
Author Contributions
Conceived and designed the experiments: AZ AGF SS PP CC. Performed the experiments: AZ
AGF SS ES EZ FB PP CC. Analyzed the data: AZ SS AAM. Contributed reagents/materials/
analysis tools: AZ SS PP CC. Wrote the paper: AZ AGF SS AAM PP CC.
References
1. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diag-
nosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive sum-
mary. Am J Respir Crit Care Med 2013; 187: 347–65. doi: 10.1164/rccm.201204-0596PP PMID:
22878278
2. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care
Med 2013; 187:228–37. doi: 10.1164/rccm.201210-1843CI PMID: 23204254
3. Paredi P, Kharitonov SA, Leak D, Paredi P, Kharitonov SA, Leak D, et al. Exhaled ethane, a marker of
lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
2000; 162:369–73. PMID: 10934055
4. Morrison D, Rahman I, Lannan S, MacNeeW. Epithelial permeability, inflammation, and oxidant stress
in air spaces of smokers. Am J Respir Crit Care Med 1999; 159:473–9. PMID: 9927360
5. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, et al. Exhaled 8-isopros-
tane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J
Respir Crit Care Med 2000; 162:1175–7. PMID: 10988150
6. Deponte M, Horst Lillig C. Enzymatic control of cysteinyl thiol switches in proteins. Biol Chem 2015;
396:401–13. doi: 10.1515/hsz-2014-0280 PMID: 25581754
7. Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates syn-
thesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethio-
nine-dependent methyltransferases. Circ Res 2000; 87:99–105. PMID: 10903992
8. Leiper J, Murray-Rust J, McDonald N, Vallance P. S-nitrosylation of dimethylarginine dimethylaminohy-
drolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylargi-
nine dimethylaminohydrolase. Proc Natl Acad Sci USA 2002; 99:13527–32. PMID: 12370443
9. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric
oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–5. PMID: 1347093
Oxidative Stress and Arginines in COPD
PLOSONE | DOI:10.1371/journal.pone.0160237 August 1, 2016 8 / 10
10. Schwedhelm E, Boger RH. The role of asymmetric and symmetric dimethylarginines in renal disease.
Nat Rev Nephrol 2011; 7: 275–85. doi: 10.1038/nrneph.2011.31 PMID: 21445101
11. Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D. Plasma concentrations of the cardiovas-
cular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and
correlate with immune activation markers. Pharmacol Res 2009; 60: 508–14. doi: 10.1016/j.phrs.2009.
07.009 PMID: 19651212
12. Boger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective
marker of cardiovascular disease and mortality—An update on patient populations with a wide range of
cardiovascular risk. Pharmacol Res 2009; 60: 481–7. doi: 10.1016/j.phrs.2009.07.001 PMID:
19596069
13. Grasemann H, Al-Saleh S, Scott JA, Shehnaz D, Mehl A, Amin R, et al. Asymmetric dimethylarginine
contributes to airway nitric oxide deficiency in patients with cystic fibrosis. Am J Respir Crit Care Med
2011; 183:1363–8. doi: 10.1164/rccm.201012-1995OC PMID: 21278301
14. Scott JA, Grasemann H. Asymmetric dimethylarginine: A disease marker for asthma? Chest 2013;
144:367–368. doi: 10.1378/chest.13-0480 PMID: 23918098
15. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine
dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24:1023–30. PMID: 15105281
16. Jiang JL, Zhang XH, Li NS, RangWQ, Feng-Ye, Hu CP,et al. Probucol decreases asymmetrical
dimethylarginine level by alternation of protein arginine methyltransferase I and dimethylarginine
dimethylaminohydrolase activity. Cardiovasc drugs ther 2006; 20: 281–94 PMID: 16897158
17. Chen Y, Xu X, Sheng M, Zhang X, Gu Q, Zheng Z. PRMT-1 and DDAHs-induced ADMA upregulation is
involved in ROS- and RAS-mediated diabetic retinopathy. Exp eye res 2009; 89:1028–34 doi: 10.1016/
j.exer.2009.09.004 PMID: 19748504
18. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, Moshal KS, Tyagi SC. Mechanisms of homocysteine-
induced oxidative stress. Am J Physiol Heart Circ Physiol 2005; 289:2649–56
19. Scott JA, Duongh M, Young AW, Subbarao P, Gauvreau GM, Grasemann H. Asymmetric dimethylargi-
nine in chronic obstructive pulmonary disease (ADMA in COPD). Int J Mol Sci 2014; 15:6062–71. doi:
10.3390/ijms15046062 PMID: 24727374
20. Carraro S, Giordano G, Piacentini G, Kantar A, Moser S, Cesca L,et al. Asymmetric dimethylarginine in
exhaled breath condensate and serum of children with asthma. Chest 2013; 144:405–10. doi: 10.1378/
chest.12-2379 PMID: 23412513
21. Scott JA, North ML, Rafii M, Huang H, Pencharz P, Subbarao P,et al. Asymmetric dimethylarginine is
increased in asthma. Am J Respir Crit Care Med 2011; 184:779–85. doi: 10.1164/rccm.201011-
1810OC PMID: 21719758
22. Aydin M, Altintas N, CemMutlu L, Bilir B3, Oran M3, Tülübaş F1 Asymmetric dimethylarginine contrib-
utes to airway nitric oxide deficiency in patients with COPD. Clin Respir J. 2015; doi: 10.1111/crj.12337
23. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; and GOLD ScientificCommittee. Global
strategy for the diagnosis, management, and prevention ofchronic obstructive pulmonary disease.
NHLBI/WHOGlobal Initiative for ChronicObstructive Lung Disease (GOLD) Workshop summary. Am J
Respir Crit Care Med 2001; 163:1256–76. PMID: 11316667
24. Zinellu A, Sotgia S, Usai MF, Pintus G, Deiana L, Carru C. Improved method for plasma ADMA, SDMA,
and arginine quantification by field-amplified sample injection capillary electrophoresis UV detection.
Anal Bioanal Chem 2011; 399:1815–21. doi: 10.1007/s00216-010-4580-0 PMID: 21181467
25. Zinellu A, Sotgia S, Scanu B, Chessa R, Gaspa L, Franconi F,et al. Taurine determination by capillary
electrophoresis with laser-induced fluorescence detection: from clinical field to quality food applica-
tions. Amino Acids 2009; 36:35–41. doi: 10.1007/s00726-007-0022-5 PMID: 18193477
26. Teerlink T. Measurement of asymmetric dimethylarginine in plasma: methodological considerations
and clinical relevance. Clin Chem Lab Med 2005; 43:1130–1138 PMID: 16197310
27. Esterbauer H, Cheeseman KH. Determination of aldehydiclipid peroxidation products: malonaldehyde
and 4-hydroxynonenal. Methods Enzymol 1990; 186:407–421 PMID: 2233308
28. Gan KN, Smolen A, Eckerson HW, La Du BN. Purification of human serum paraoxonase/arylesterase.
Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19:100–6. PMID:
1673382
29. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82:70–7. PMID: 13650640
30. Lopez AD, Murray CC. The global burden of disease, 1990–2020. Nat Med 1998; 4: 1241–3. PMID:
9809543
31. Barnes PJ, Kleinert S. COPD-A neglected disease. Lancet 2004; 364:564–5. PMID: 15313342
Oxidative Stress and Arginines in COPD
PLOSONE | DOI:10.1371/journal.pone.0160237 August 1, 2016 9 / 10
32. Keatings VM, Barnes PJ. Granulocyte activation markers in induced sputum:comparison between
chronic obstructive pulmonary disease, asthma, andnormal subjects. Am J Respir Crit Care Med 1997;
155:449–53. PMID: 9032177
33. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to
symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55:114–20. PMID:
10639527
34. Retamales I, Elliott WM, Meshi B, Coxson HO, Pare PD, Sciurba FC,et al. Amplification of inflammation
in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001;
164:469–73 PMID: 11500352
35. Koechlin C, Maltais F, Saey D, Michaud A, LeBlanc P, Hayot M, et al. Hypoxaemia enhances peripheral
muscle oxidative stress in chronic obstructive pulmonary disease. Thorax 2005; 60:834–41. PMID:
15964914
36. Hoppeler H, Vogt M, Weibel ER, Flück M. Response of skeletal muscle mitochondria to hypoxia. Exp
Physiol 2003; 881:109–19.
37. Chandel NS, Schumacker PT. Cellular oxygen sensing by mitochondria: old questions, new insight. J
Appl Physiol 2000; 88:1880–9 PMID: 10797153
38. Rossi R, Giustarini D, Milzani A, Dalle-Donne I. Cysteinylation and homocysteinylation of plasma pro-
tein thiols during ageing of healthy human beings. J Cell Mol Med 2009; 13:3131–40. doi: 10.1111/j.
1582-4934.2008.00417.x PMID: 18624771
39. McEvoy MA, Schofield PW, Smith WT, Agho K, Mangoni AA, Soiza RL,et al. Serummethylarginines
and spirometry-measured lung function in older adults. PLoS One 2013; 8:e58390 doi: 10.1371/journal.
pone.0058390 PMID: 23690915
40. Bode-Boger SM, Scalera F, Ignarro LJ. The L-arginine paradox: importance of the L-arginine/asymmet-
rical dimethylarginine ratio. Pharmacol Ther 2007; 114:295–306. PMID: 17482266
41. Caldwell RB, Toque HA, Narayanan SP, Caldwell RW. Arginase: an old enzyme with new tricks. Trends
Pharmacol Sci 2015; 36:395–405 doi: 10.1016/j.tips.2015.03.006 PMID: 25930708
42. Bulau P, Zakrzewicz D, Kitowska K, Leiper J, Gunther A, Grimminger F, et al. Analysis of methylargi-
nine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Phy-
siol Lung Cell Mol Physiol 2007; 292:18–24.
43. Renkema TE, Postma DS, Noordhoek JA, Sluiter HJ, Kauffman HF. In vitro release of neutrophil elas-
tase, myeloperoxidase and beta-glucuronidase in patients with emphysema and healthy subjects. Eur
Respir J 1991; 4:1237–1244 PMID: 1666565
44. Hogg JC, Chu S, Utokaparch R, Woods R, Elliott WM, Buzatu L, et al The nature of small-airway
obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2645–2653 PMID:
15215480
Oxidative Stress and Arginines in COPD
PLOSONE | DOI:10.1371/journal.pone.0160237 August 1, 2016 10 / 10
